Results 61 to 70 of about 10,399 (159)
Objective: to evaluate the prognostic value of the THRIVE scale in patients aged 60 years and older with ischemic stroke (IS) after intravenous thrombolysis with Fortelyzin® (INN/chemical name – recombinant protein containing the amino acid sequence of ...
N. A. Shamalov +13 more
doaj +1 more source
Dual antiplatelet versus alteplase in anterior and posterior circulation minor stroke
Objective The Antiplatelet versus R-tPA for Acute Mild Ischaemic Stroke trial has demonstrated the non-inferiority of dual antiplatelet therapy (DAPT) to alteplase in minor non-disabling stroke.
Yu Cui, Hui-Sheng Chen
doaj +1 more source
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase
Josef YayanDepartment of Internal Medicine, Vinzentius-Hospital, Landau, GermanyAbstract: Alteplase (recombinant tissue plasminogen activator) has been used in the treatment of acute ischemic stroke for 10 years.
Yayan J
doaj
Effectiveness of alteplase in the very elderly after acute ischemic stroke
Josef Yayan Department of Internal Medicine, University Hospital of Saarland, Homburg/Saar, Germany Abstract: Alteplase has traditionally been the only pharmacologic agent available for treating acute ischemic stroke worldwide, and is considered an ...
Yayan J
doaj
IntroductionEndovascular thrombectomy (EVT) and concomitant usage of intravenous alteplase (alteplase) in large vessel occlusion stroke may produce unwanted excess intracerebral hemorrhage (ICH). Whether this applies specifically to isolated occlusion of
Slaven Pikija +10 more
doaj +1 more source
BackgroundTenecteplase has been proposed as a practical alternative to alteplase for intravenous thrombolysis in acute ischemic stroke. Although randomised trials have demonstrated noninferiority, data from real-world comparative cohorts remain limited ...
Weili Zhao +4 more
doaj +1 more source
Background: Tenecteplase (TNK) is a novel thrombolytic agent gaining attention as an alternative to alteplase for treating acute ischemic stroke (AIS).
Muhammad Hassan Waseem +9 more
doaj +1 more source
Recombinant tissue-type plasminogen activators (rtPA) effectively dissolve blood clots and improve symptoms in patients with acute ischemic stroke and myocardial infraction.
Tsuyoshi Nakai +6 more
doaj +1 more source
Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System
Purpose. Alteplase is the standard of care for intravenous thrombolytic treatment of acute ischemic stroke, but recent evidence suggests that tenecteplase may be as safe and efficacious. The purpose of this study was to evaluate the direct cost savings,
Alexis Pace, Maya Wai, Ethan Frye
doaj
Early Reperfusion in Basilar Artery Occlusion Stroke Managed With Tenecteplase Versus Alteplase Before Endovascular Treatment. [PDF]
Wolman DN +38 more
europepmc +1 more source

